Zura Bio Limited Class A Ordinary Shares (ZURA)

Zura Bio Limited Class A Ordinary Shares (ZURA) is a Biotechnology company in the Healthcare sector listed on the NASDAQ.

As of Oct 23, 2026: market cap $396M; returns 1 day -4.8%, 1 week -13.4%, 1 year +0.0%.

Zura Bio Limited is a clinical-stage immunology biotechnology company specializing in the development of dual-pathway antibodies for autoimmune and inflammatory diseases. The company's business model is pre-revenue, focused on the clinical advancement of its three primary assets: tibulizumab (ZB-106), crebankitug (ZB-168), and torudokimab (ZB-880).

Groups ZURA belongs to

• Clinical Stage Biotech
• Biotechnology
• Autoimmune Diseases
• Healthcare
• Bispecific Antibodies
• Monoclonal Antibodies
• Antibody Therapeutics
• Chronic Inflammatory Diseases
• Biopharmaceutical
• Life Sciences

ZURA financial model: income statement, cash flow and balance sheet